Abstract: A method including the steps of: (a) providing trans-cis nepetalactone; (b) providing sodium bicarbonate; (c) providing water; (d) providing methanol; (e) mixing the trans-cis nepetalactone, the sodium bicarbonate, the water, the methanol as a reaction mixture for approximately 15 hours at ambient temperature and pressure; (f) converting at least 95.2% of the nepetalactone to a ring open ester and/or aldehyde; (g) removing unreacted sodium bicarbonate via filtration; (h) transferring the filtered reaction mixture to a hydrogenation apparatus; (i) charging the hydrogenation apparatus with Raney nickel and/or Urushibara nickel; and (j) hydrogenating the ring open ester and/or aldehyde to generate at least one of DHN1, DHN2, and DHN3.

Abstract: Provided are methods of preparing cannabinoids and cannabinoid derivatives and compositions containing the cannabinoids and derivatives.

Abstract: Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. The compounds can be used to identify reactive nucleophilic amino acid residues, such as reactive tyrosines and reactive lysines, in proteins and to modify the activity of proteins with reactive nucleophilic amino acid residues via the formation of protein adducts comprising a fragment of the compounds. Methods are also described for screening the compounds to identify ligands of proteins comprising a reactive lysine or a reactive tyrosine.

Abstract: Disclosed are novel fused mescaline derivative compounds, notably substituted N-propylamine fused heterocyclic mescaline derivatives, including substituted N-propylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

Abstract: Compound I of the formula and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.

Abstract: The present application relates to large-scale methods of uniformly coating packaging surfaces with a benzoxaborole compound.

Abstract: A method for synthesizing 3-bromo-5-(2-ethylimidazo[1,2-a] pyridine-3-carbonyl)-2-hydroxybenzonitrile, particularly relates to a method for synthesizing a compound represented by a formula (III), and particularly relates to step A or step B; step A: a compound represented by a formula (I) and a compound represented by a formula (II) are first heated in an organic solvent to react, and the resulting reaction product and a base are heated in the presence of water to continue the reaction to obtain a compound represented by a formula (III); and step B: a compound represented by the formula (I), a compound represented by a formula (II), and a base are heated in an organic solvent to react, and the resulting reaction product is heated in the presence of water to continue the reaction to obtain a compound represented by a formula (III).

Abstract: The present invention is based on the finding that the inhibition of the proliferation of cancer cells by cannabinoids is brought about more effectively by combined treatment with low dose naltrexone (LDN) or 6-?-naltrexone (6BN), a metabolite of naltrexone. There is provided a pharmaceutical composition comprising naltrexone or a metabolite thereof or an analogue thereof, for use in the treatment of cancer within a subject, wherein a therapeutically effective amount of the naltrexone or metabolite thereof or analogue of either is to be administered to the subject in a first treatment phase, wherein after the first treatment phase the subject is to be administered a therapeutically effective amount of a cannabinoid in a second treatment phase.

Abstract: Novel polycyclic compounds, synthesis methods and applications thereof are provided. The compound comprise a plurality of carbocyclic and/or heterocyclic structures having at least one group that emits visible light or fluorescence and at least one ultraviolet and/or visible (blue) light absorbing group covalently bonded to provide stability. The compounds can be used as a light conversion agent, dye, pigment, fluorescence agent, ultraviolet light or blue light absorber, and is applied to optical film, agricultural film, optical disk (disc), optical lens, goggles, skin care, makeup, lighting, coatings, adhesives, light stabilizers, or panels.

Abstract: The invention relates to a process for preparing a monohydrate potassium salt of a 5 thienopyridone derivative. It also relates to a monohydrate potassium salt of a thienopyridone derivative and its use in medicine, in particular for treating or preventing metabolic disorders, such as NASH.

Abstract: The present disclosure provides a compound and methods of preparing the compound. The compound has anti-microbial and anti-mite properties and can be bonded to materials such as fiber and synthetic polymer. The compound may also be used in a finishing agent for textiles, fibers, or yarns to protect these materials against microorganisms and mites. Additionally, when these materials are treated with a relatively low dosage of the compound, long-lasting and effective anti-mold and anti-mite effects may be achieved at a relatively low cost.

Abstract: The present technology relates to processes, mixtures and intermediates useful for making picolinamide fungicides. The picolinamide compounds are prepared by processes that include coupling together a 4-methoxy-3-acyloxypicolinic acid with key 2-amino-L-alaninate esters derived from substituted 2-phenylethanols.

Abstract: A process for chiral separation of ethyl 3-amino-1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]pyrazole-4-carboxylate (VI) from the racemic mixture of ethyl 3-amino-1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]pyrazole-4-carboxylate and ethyl 3-amino-1-[(3S,4R)-4-cyanotetrahydropyran-3-yl]pyrazole-4-carboxylate (V).

Abstract: Provided are methods of preparing cannabinoids and cannabinoid derivatives and compositions containing the cannabinoids and derivatives.

Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).

Abstract: Disclosed herein are small molecule inhibitors of platelet function, and methods of using the small molecules to treat diseases, such as platelet hemostasis and thrombosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

Abstract: A method of producing refined oils and/or fats whereby the content of, e.g., glycidol, can be reduced and reductions in the content of tocopherols can be inhibited, and a method for producing low-impurity tocopherols. The method includes a first distillation step of subjecting raw material oils and/or fats to thin film distillation under a first condition; a second distillation step of subjecting a first distillate fraction obtained after the first distillation step to thin film distillation under a second condition; a third distillation step of subjecting a second residual fraction obtained after the second distillation step to thin film distillation under a third condition; and a mixing step of obtaining a mixed oil by mixing a first residual fraction obtained after the first distillation step, with a third distillate fraction obtained after the third distillation step. The first, second, and third conditions include specified temperature conditions and pressure conditions.

Abstract: The present invention relates to a process according to Scheme 1 for the preparation of microbiocidal 5-trifluoromethyl-1,2,4-oxadiazole derivatives of formula (I) suitable for use, e.g., as active ingredients, which have microbiocidal activity, in particular, fungicidal activity.

Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.